STOCK TITAN
  1. Home
  2. Sec-filings
  3. CRL
  4. [Form 4] CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Insider Trading Activity

Director Virginia M. Wilson (CRL) receives 1,438-share equity award at Charles River

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Charles River Laboratories International director Virginia M. Wilson received an equity award. On 5/8/2026 she was granted 1,438 shares of Common Stock, valued at $177.62 per share, as a grant or award. After this acquisition, she directly holds 6,349 shares. According to the disclosure, these unvested restricted stock units will vest on the earlier of 5/8/2027 or the business day before the company’s next annual meeting of shareholders.

Positive

  • None.

Negative

  • None.
Insider WILSON VIRGINIA M
Role null
Type Security Shares Price Value
Grant/Award Common Stock 1,438 $177.62 $255K
Holdings After Transaction: Common Stock — 6,349 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Equity award size 1,438 shares Grant of Common Stock on May 8, 2026
Award valuation price $177.62 per share Reference price for the granted shares
Post-transaction holdings 6,349 shares Total Common Stock directly held after grant
Vesting date threshold May 8, 2027 Latest vesting date for unvested restricted stock units
restricted stock units financial
"The unvested restricted stock units vest upon the earlier of 5/8/2027 or the business day prior to the Company's next annual meeting of shareholders."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
annual meeting of shareholders regulatory
"The unvested restricted stock units vest upon the earlier of 5/8/2027 or the business day prior to the Company's next annual meeting of shareholders."
A yearly gathering where a company’s owners (shareholders) vote on key items like electing the board, approving executive pay, and ratifying auditors, and receive updates on performance and strategy. Think of it as an annual town hall for owners: it matters to investors because outcomes and disclosures can affect leadership, corporate direction, dividend and governance policies, and therefore the company’s risk and potential return.
Grant, award, or other acquisition regulatory
"transaction_code_description: Grant, award, or other acquisition"
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
WILSON VIRGINIA M
(Last)(First)(Middle)
C/O CHARLES RIVER LABORATORIES
251 BALLARDVALE STREET
(Street)
WILMINGTON MASSACHUSETTS 01887
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. [ CRL ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/08/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/08/2026A1,438(1)A$177.626,349D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The unvested restricted stock units vest upon the earlier of 5/8/2027 or the business day prior to the Company's next annual meeting of shareholders.
/s/ Virginia M. Wilson05/11/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did CRL director Virginia M. Wilson report?

Virginia M. Wilson reported receiving an equity award of 1,438 shares of Charles River Laboratories Common Stock. The award is classified as a grant or other acquisition and reflects part of her director compensation, not an open-market purchase.

At what price was Virginia M. Wilson’s CRL stock award valued?

The 1,438-share award was valued at $177.62 per share. This valuation helps quantify the size of the compensation grant in dollar terms and indicates the reference share price used for this restricted stock unit award.

How many CRL shares does Virginia M. Wilson hold after this grant?

Following the grant, Virginia M. Wilson directly holds 6,349 shares of Charles River Laboratories Common Stock. This total reflects her updated beneficial ownership as reported in the filing after the restricted stock unit award.

When do Virginia M. Wilson’s CRL restricted stock units vest?

The unvested restricted stock units vest on the earlier of May 8, 2027, or the business day before Charles River Laboratories’ next annual meeting of shareholders. This vesting schedule ties the award to both time and the company’s annual governance cycle.

Was Virginia M. Wilson’s CRL transaction a market buy or a compensation award?

The transaction is a compensation-related grant, not a market purchase. It is coded as a grant, award, or other acquisition, meaning shares were awarded to her as part of her role rather than acquired through open-market buying.